Introduction
The Global Biologics Market size is expected to be worth around US$ 893.83 Billion by 2032 from US$ 417 Billion in 2023, growing at a CAGR of 9.10% during the forecast period from 2023 to 2032. In 2023, North America reaching a revenue total of US$ 183.4 Billion.
This growth is driven by the enhanced efficacy of biologics in treating complex diseases such as cancer, diabetes, and autoimmune disorders. The sector is also benefiting from significant innovation, particularly with the rise of first-in-class biologic drugs that utilize novel treatment mechanisms. In 2022, these innovative therapies accounted for over half of newly approved drugs, highlighting the industry’s focus on targeted and transformative treatments.
The biologics market is further bolstered by robust research and development (R&D) investments, driving advancements in therapies like gene and cell treatments. These personalized medicine approaches are revolutionizing patient care by tailoring treatments to individual genetic profiles, improving outcomes significantly. Both large pharmaceutical companies and biotech firms are contributing to this surge in R&D, showcasing a unified effort to enhance healthcare solutions.
The increasing prevalence of biosimilars is reshaping market dynamics by offering cost-effective alternatives to biologic drugs. As biosimilars gain traction, they are creating competitive pricing pressures and expanding access to biologic treatments, especially in cost-sensitive regions. This trend is expected to play a pivotal role in shaping the competitive landscape.
Global health initiatives emphasize the importance of biologics in managing health crises, as demonstrated during the COVID-19 pandemic. The rapid development and deployment of vaccines showcased the critical role of biologics in emergency responses. For instance, the February 2021 partnership between GlaxoSmithKline plc (GSK) and CureVac N.V. to develop mRNA vaccines targeting COVID-19 variants highlights ongoing advancements in vaccine technology.
Further progress is evident in Bristol Myers Squibb’s (BMS) announcement of a new cell therapy manufacturing facility in the Netherlands in April 2021. This facility will enhance BMS’s capacity to deliver advanced cancer treatments, reinforcing the industry’s commitment to personalized medicine. These developments reflect a vibrant pipeline of innovation, focusing on mRNA technologies and cell therapies, marking a transformative era of healthcare advancements.
Key Takeaways
- Market Size: Biologics Market size is expected to be worth around US$ 893.83 Billion by 2032 from US$ 417 Billion in 2023, growing at a CAGR of 9.10% during the forecast period from 2023 to 2032
- Market Growth: The global biologics market is expanding at a compound annual growth rate of 9.10%, driven by increased demand and technological advancements.
- Dominant Segment: Microbial expression systems, such as yeast and E. coli, were key in biopharmaceutical production in 2022, utilized by Novartis and Johnson & Johnson.
- Revenue Leaders: Monoclonal antibodies (MABs) accounted for the largest revenue share due to their application in various therapeutic areas.
- Oncology Segment: The oncology segment led in revenue because of significant R&D investments and product adoption to reduce chemotherapy side effects.
- Manufacturing Trends: Manufacturing is crucial in biologics production, with in-house production becoming increasingly prevalent among companies.
- Distribution Channels: Hospital and online distribution channels are projected to grow rapidly, expanding accessibility to biologics.
- Market Drivers: Advances in biomedical science, including nanobodies and antisense RNAi therapeutics, are key drivers of market growth.
- Regional Insights: North America led the market in 2022 due to a high number of FDA-approved biologics and substantial R&D investments.
Biologics Statistics
- Biologics Expenditures (2013-2017):
- In 2017, biologics constituted less than 2% of prescriptions but accounted for nearly 40% of all medication expenditures in the United States.
- Global Availability of Biosimilars (as of 2019):
- Infliximab biosimilars were available in 43 countries, with a median entry year of 2015.
- Trastuzumab biosimilars were available in 31 countries.
- Pegfilgrastim biosimilars were accessible in 27 countries.
- Bevacizumab biosimilars were limited to only 7 countries.
- Biosimilars were prevalent in highand upper-middle-income nations, with over 80% availability for adalimumab, etanercept, and pegfilgrastim in OECD countries.
- Outside OECD countries, filgrastim biosimilars had a 57.9% availability rate.
- In Europe, availability was high for adalimumab (92.4%), etanercept (80.0%), infliximab (62.8%), pegfilgrastim (81.5%), and trastuzumab (74.2%).
- FDA Approvals (2015-2022):
- The lowest number of total drug approvals (NCEs and biologics) occurred in 2016 (22) and 2022 (37).
- Fifteen biologics were approved in 2022, with seven (46%) receiving Orphan Drug Status.
- In 2022, six biologics targeted cancer treatments, continuing a pattern seen in 2019 (four), 2020 (eight), and 2021 (six).
- Biosimilars in the US (as of May 2023):
- 40 biosimilars were FDA-approved, with 27 available in the US market.
- Among these, four biosimilars were designated as interchangeable.
- Trends and Projections:
- In 2022, biologics accounted for 40% of all pharmaceutical approvals, signaling stabilization and growth in their market presence.
Emerging Trends
- AI Integration: Artificial intelligence (AI) is revolutionizing the biologics industry by streamlining drug discovery and development. AI enables researchers to identify novel drug targets and optimize clinical trial designs by efficiently analyzing large datasets. This accelerates the identification of potential biologic candidates and improves trial outcomes. In 2022, the AI market in life sciences was valued at $1.5 billion and is expected to grow significantly as AI’s role in healthcare expands. Companies are increasingly adopting AI technologies to enhance research and development processes, offering opportunities for innovation and cost efficiency.
- Gene Editing Advancements: Gene editing tools, especially CRISPR-Cas9, are transforming treatment possibilities for genetic diseases. CRISPR-Cas9 facilitates precise genetic modifications, enabling the correction of mutations at their source. For example, Casgevy, a CRISPR-based therapy, addresses blood disorders by modifying genes to produce functional hemoglobin. As this technology evolves, its applications are expected to expand, offering targeted therapies for a range of conditions and significantly improving patient outcomes. Gene editing is unlocking potential for treatments previously considered unattainable.
- Rise of Biosimilars: Biosimilars, cost-effective alternatives to biologic drugs, are gaining traction due to patent expirations on major biologics. These near-identical versions maintain similar safety and efficacy profiles, increasing access for patients while fostering competition. Biosimilars are contributing to reduced healthcare costs without compromising quality, benefiting both patients and healthcare systems. Their growing prevalence is reshaping the pharmaceutical market by driving innovation and affordability.
- Multi-omics Approaches: The integration of genomics, proteomics, and other omics technologies is providing a comprehensive understanding of diseases. Known as multi-omics, this approach aids in personalized medicine by identifying biomarkers and molecular pathways essential for disease progression. These insights lead to targeted therapies tailored to individual patients, improving treatment outcomes. As multi-omics technologies advance, they are expected to play a pivotal role in precision medicine, offering a holistic perspective on health and disease management.
- Partnerships and Collaborations: The biopharmaceutical industry is witnessing an increase in collaborations to harness advanced technologies and expand drug pipelines. In the first quarter of 2024, partnerships totaled $36 billion in value. These alliances help companies share resources, expertise, and technologies, accelerating drug development and reducing costs. Partnerships enable faster delivery of innovative therapies to market, fostering growth and innovation in biologics. This trend is expected to continue, enhancing the industry’s ability to address complex healthcare challenges.
Use Cases
- Cancer Treatment: Biologics play a transformative role in oncology by targeting specific cancer cells with monoclonal antibodies. Companies like Gilead Sciences are at the forefront of developing antibody-based therapies, which bind to cancer cells and signal the immune system to destroy them. Recent advancements, including deals exceeding $1 billion, highlight the value of biologics in precision medicine, offering effective and personalized treatment options for cancer patients.
- Autoimmune Diseases: Biologics are revolutionizing treatment for autoimmune conditions such as rheumatoid arthritis by modulating the immune system. These therapies target specific pathways to reduce inflammation and prevent damage, providing improved outcomes for patients unresponsive to traditional treatments. With the introduction of new biologic drugs, patients now have access to tailored therapies that enhance quality of life and disease management.
- Infectious Diseases: Vaccines are a key application of biologics, particularly mRNA vaccines. Innovations like Moderna’s mRNA-1345 vaccine for respiratory syncytial virus (RSV) in adults over 60 illustrate biologics’ potential in reducing disease risk. By instructing cells to produce proteins that trigger immune responses, mRNA technology is revolutionizing infectious disease prevention. The success of COVID-19 vaccines has accelerated research, paving the way for future biologic vaccines against diverse infectious diseases.
- Rare Genetic Disorders: Gene therapy, a biologic innovation, offers hope for rare genetic disorders by repairing or replacing faulty genes. Approved therapies like Casgevy for sickle-cell disease demonstrate the potential to treat previously untreatable conditions. By addressing genetic root causes, gene therapy provides long-term solutions and potential cures. Ongoing research is expanding applications, underscoring biologics’ promise in personalized medicine.
- Neurological Disorders: Biologics are advancing treatments for neurological diseases such as Alzheimer’s disease by targeting proteins and pathways involved in disease progression. These therapies aim to slow degeneration, alleviate symptoms, and improve patient quality of life. By addressing the complex mechanisms of neurodegenerative diseases, biologics represent a significant breakthrough, offering new hope for patients and caregivers managing these challenging conditions.
Conclusion
The biologics market is experiencing transformative growth driven by advancements in precision medicine, innovative therapies, and increasing adoption of biosimilars. With significant investments in R&D, technologies such as gene editing, multi-omics, and AI are reshaping drug discovery and enhancing patient outcomes. Biologics’ dominance in oncology, autoimmune, infectious, and rare genetic disorder treatments underscores their impact on healthcare.
Moreover, collaborations and cost-effective biosimilars are fostering accessibility and competitive dynamics. Expected to reach USD 893.83 billion by 2032, the biologics market exemplifies a pivotal shift toward personalized and targeted therapies, marking a new era in the global healthcare landscape.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
